Antibody, Immunoglobulin, Or Fragment Thereof Fused Via Peptide Linkage To Nonimmunoglobulin Protein, Polypeptide, Or Fragment Thereof (i.e., Antibody Or Immunoglobulin Fusion Protein Or Polypeptide) Patents (Class 424/134.1)
  • Patent number: 11976121
    Abstract: Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD123-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD123-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 7, 2024
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Marco L. Davila
  • Patent number: 11959118
    Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: April 16, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Terrance A. Stadheim, Dongxin Zha, Liming Liu
  • Patent number: 11951166
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 9, 2024
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • Patent number: 11931421
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: March 19, 2024
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Scott Hilderbrand, Timothy Weeden, John Najim, Stefano Zanotti, Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Kim Tang, Brendan Quinn
  • Patent number: 11932679
    Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: March 19, 2024
    Assignees: Keio University, Nagoya Institute of Technology
    Inventors: Toshihide Kurihara, Yusaku Katada, Hiromitsu Kunimi, Kazuo Tsubota, Hideki Kandori
  • Patent number: 11918634
    Abstract: The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 184, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: March 5, 2024
    Assignee: GOOD T CELLS, INC.
    Inventors: Jung Ho Kim, Beom Seok Kim
  • Patent number: 11912779
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: February 27, 2024
    Inventors: Barbora Malecova, Rob Burke, Beatrice Diana Darimont, David Sala Cano
  • Patent number: 11872241
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 16, 2024
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • Patent number: 11866742
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: January 9, 2024
    Inventors: Anastasia Henry, Mihalis S. Kariolis, Cathal S. Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman
  • Patent number: 11857623
    Abstract: The invention is directed to a protein construct comprising a scaffold protein into which an IgE epitope containing motif is inserted or substituted. The protein construct may be used as an antigen, immunogen or vaccine to induce immune responses against IgE in a vaccinated subject thereby reducing the severity of allergic phenomena associated with IgE. The invention is also directed to a method for designing such a protein construct and expressing it using recombinant DNA methods.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: January 2, 2024
    Assignee: King Abdulaziz University
    Inventor: Sari Sabban
  • Patent number: 11859006
    Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 2, 2024
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Sho Tsukamoto, Keigo Kumagai, Shinnosuke Tsuji
  • Patent number: 11851492
    Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: December 26, 2023
    Assignee: Merck Patent GmbH
    Inventors: Josef Straub, Eike Staub
  • Patent number: 11845781
    Abstract: The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: December 19, 2023
    Inventors: Shenglong Zhu, Yongquan Chen, Zhen Wang
  • Patent number: 11840570
    Abstract: The invention relates to a method of removing immune suppression in a tumor microenvironment or stimulating an immune system against cancer cells, comprising administering to a subject a combination of a HDAC inhibitor and an NSAID in combination with an immune checkpoint inhibitor.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: December 12, 2023
    Assignee: Great Novel Therapeutics Biotech & Medicals Corporation
    Inventors: Jia-Shiong Chen, Ye-Su Chao, Chia-Nan Chen
  • Patent number: 11840557
    Abstract: Novel therapeutic agents, particularly those capable of activating (GPR)124/RECK/Frizzled/lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, while not activating Frizzled/LRP-mediated Wnt signaling in the absence of RECK and/or GPR124. The agents are particularly useful for the prevention or treatment of neurovascular disorders or central nervous system (CNS) disorders including neurovascular dysfunction.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 12, 2023
    Inventor: Benoit Vanhollebeke
  • Patent number: 11820807
    Abstract: A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: November 21, 2023
    Inventors: Chang-Yi Wang, Wen-Jiun Peng, Wei-Ting Kao
  • Patent number: 11814419
    Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: November 14, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Andrew Kruse, Aashish Manglik, Irving L. Weissman, Roy Louis Maute, Melissa N. McCracken, Sydney Gordon
  • Patent number: 11795235
    Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 24, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
  • Patent number: 11789010
    Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 17, 2023
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, Barbara Sennino, Susannah D. Barbee, Ursula Jeffry
  • Patent number: 11780923
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 10, 2023
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Patent number: 11739163
    Abstract: The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 29, 2023
    Assignee: AEBI LTD.
    Inventors: Ilan Morad, Hanan Itzhaki
  • Patent number: 11739118
    Abstract: The disclosure relates to chromatography ligands, e.g., chromatography ligands comprising at least two binding units and at least one spacer domain, wherein each binding unit comprises one or two immunoglobulin binding domains.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: August 29, 2023
    Assignee: Bioprocessia Technologies LLC
    Inventor: Yinong Zong
  • Patent number: 11731937
    Abstract: The present disclosure provides derivatives of amino acids that have surface-active properties. The amino acid can be naturally-occurring or synthetic, or they may be obtained via a ring-opening reaction of a lactam, such as caprolactam. The amino acid may be functionalized to form a compound that is surface-active and have advantageous surfactant characteristics. The compounds of the present disclosure have low critical micelle concentrations (CMC) as well as superior ability to lower the surface tension of a liquid.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: August 22, 2023
    Assignee: AdvanSix Resins & Chemicals LLC.
    Inventors: Edward Asirvatham, Andrei Honciuc, Voichita Mihali
  • Patent number: 11718671
    Abstract: Provided is a novel antibody and a method for treating breast cancer. More specifically, the present disclosure relates to a bispecific antibody targeting CD3 and a tumor antigen target such as HER2, a preparation method, and uses thereof. The present disclosure also relates to a composition containing said antibody and a method for treating cancer by using the antibody.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 8, 2023
    Assignee: Excelmab, Inc.
    Inventors: Wenjun Zhang, Cuijuan Chen, Xuemei Wei, Tonghui Luo
  • Patent number: 11692027
    Abstract: The present disclosure provides pharmaceutical compositions for monoclonal antibodies, antibody-related products, therapeutic proteins, peptides and other biopharmaceuticals. The compositions provide initial and long term stability of the biopharmaceutical agent, rendering them suitable for parenteral, pulmonary, transdermal, topical, intradermal, intrascleral, intracorneal, ocular and other forms of delivery. The compositions and methods lead to higher yields in dilute solutions and reduce unwanted aggregation of the biopharmaceutical agent. The compositions and methods also allow for disaggregation of previously aggregated proteins and protection from aggregation upon dilution. Additionally, provided are non-aggregating antibody reagents for analytical immunoassays including ELISA methods. The invention provides compositions and methods for topical, enteral, parenteral, pulmonary and other forms of delivery of biologically active substances.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Edward R. Kraft, Steven Andrew Giannos, Bernard Godley
  • Patent number: 11680101
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 20, 2023
    Assignee: KYMAB LIMITED
    Inventors: Joana De Abreu Carvalho, Steve Holmes, Allan Lawrie
  • Patent number: 11667900
    Abstract: Provided are Shp2- and Spleen tyrosine kinase (Syk)-integrated sensing and actuating protein (iSNAP) (Shp2- and Syk-iSNAP) chimeric proteins comprising: a bi-phosphorylatable peptide, optionally a bisphosphoryl tyrosine-based activation (BTAM) motif; a Fluorescent Protein (FP) Förster Resonance Energy Transfer (FRET) (or FP FRET) pair or pair of motifs; a truncated Shp2 domain comprising an N-Src Homology 2(N-SH2) domain and a C-Src Homology 2(C-SH2) domain; and, a phosphatase (PTP) domain or a kinase domain. Provided are engineered cells and methods for cancer cell or tumor eradication, or for the treatment or amelioration of a cancer, tumor or dysfunctional cell, or for promoting an anti-cancer, anti-tumor or anti-dysfunctional cell inflammatory response, including enhancing macrophage-, monocyte-, microglia-, osteoclast-, Kupffer cell- or dendritic cell-mediated antibody- or monoclonal antibody (mAb)-guided cancer or dysfunctional cell or tumor eradication, amelioration, or treatment.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: June 6, 2023
    Assignee: The Regents of the University of California
    Inventors: Yingxiao Wang, Shu Chien, Lei Lei, Shaoying Lu, Jie Sun
  • Patent number: 11648309
    Abstract: The application discloses method of treatment of cancer utilizing a linear or substantially linear epitope on netrin-1 that likely corresponds to the specific binding region of netrin-1 to receptor, in particular of the UNC5 class, especially UNC5B and UNC5A, or alternatively corresponds to a region nearby the specific binding region of netrin-1 to receptor that when bound to an antibody prevents netrin-1/receptor interaction. This determination of a linear epitope allows for the production of antibodies binding to netrin-1 and interfering with netrin-1/receptor interaction, thereby inducing apoptosis or cell death of tumour cells expressing or overexpressing netrin-1 and at least one netrin-1 receptor, owing the fact that this interaction inhibits netrin-1 binding to a receptor and the multimerization of the receptor. The application also discloses a murine monoclonal antibody directed against this epitope and various humanized forms thereof.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 16, 2023
    Assignee: NETRIS PHARMA
    Inventors: Jean-Guy Delcros, Yann Dean
  • Patent number: 11644468
    Abstract: The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 9, 2023
    Assignee: Progastrine et Cancers S.à r.L
    Inventor: Alexandre Prieur
  • Patent number: 11640845
    Abstract: A bioinformatics method for determining a risk score that indicates a risk that a subject will experience a negative clinical event within a certain period of time. The risk score is based on a combination of activities of two or more cellular signaling pathways in a subject, such as a human, wherein the specific cellular signaling pathways are the PI3K pathway and one or more of a Wnt pathway, an ER pathway, and an HH pathway. The invention also includes an apparatus with a digital processor configured to perform such a method, to a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and to a computer program comprising program code means for causing a digital processing device to perform such a method. The invention achieves advanced prognosis of negative clinical events, for example, disease progression, recurrence, development of metastasis, or even death.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: May 2, 2023
    Inventors: Hendrik Jan Van Ooijen, Wilhelmus Franciscus Johannes Verhaegh, Anne Godefrida Catharina Van Brussel, Janneke Wrobel, Robert Van Gog
  • Patent number: 11636924
    Abstract: The invention relates to a method for a computer device, for detecting an optimal candidate compound based on a plurality of samples comprising a cell line and one or more biomarkers, and a plate map configuration, wherein the plate map configuration is providing locations of samples comprising cell lines exposed to one or more biomarkers and different concentrations of a candidate compound forming at least one concentration gradient, the candidate compound being comprised in a plurality of candidate compounds, said method comprising generating (310) phenotypic profiles of each concentration gradient of each of the plurality of candidate compounds at a plurality of successive points in time to form a plurality of compound profiles, wherein generating phenotypic profiles comprises the steps obtaining (312) image data depicting each sample comprised in the concentration gradient, generating (314) a class-label and a class for each cell of the samples based on the image data, detecting (320) the optimal candidat
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: April 25, 2023
    Assignee: Molecular Devices, LLC
    Inventors: Emmanuel Israel Fuentes, Gopal Biligeri Avinash, Robert John Graves, Abhijit Vijay Thatte, Afek Kodesh, Jeffery Caron, Sharmistha Das
  • Patent number: 11630111
    Abstract: The present invention relates to a method for quantifying an anti-TNF antibody in a sample of a human individual comprising a step of adding to a test sample which may contain therapeutic anti-TNF antibodies a known amount of two or more labeled forms of said anti-TNF antibodies.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 18, 2023
    Inventors: Dorothée Lebert, Guillaume Picard
  • Patent number: 11596667
    Abstract: A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 7, 2023
    Assignee: IVERIC bio, Inc.
    Inventor: Kourous Rezaei
  • Patent number: 11591407
    Abstract: The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to enhance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and/or treatment of a cancer.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 28, 2023
    Inventors: Michele De Palma, Mario Leonardo Squadrito
  • Patent number: 11590214
    Abstract: The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: February 28, 2023
    Assignee: Danmarks Tekniskte Universitet
    Inventors: Sine Reker Hadrup, Vibeke Mindahl Rafa, Søren Nyboe Jakobsen
  • Patent number: 11548934
    Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 10, 2023
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
  • Patent number: 11530251
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: December 20, 2022
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Patent number: 11530420
    Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A and B are nucleic acid sequences encoding a first and a second polypeptide of interest (POI); and X is a nucleic acid sequence which encodes a cleavage site, wherein either the first or second POI is a transmembrane protein which comprises an intracellular retention signal.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: December 20, 2022
    Inventors: Martin Pulé, Shaun Cordoba
  • Patent number: 11525000
    Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: December 13, 2022
    Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
  • Patent number: 11524998
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: December 13, 2022
    Assignee: NOVARTIS AG
    Inventors: Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
  • Patent number: 11503813
    Abstract: Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: November 22, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jose F. Rojas, Ka-Man Venus Lai, Andrew J. Murphy, Cagan Gurer
  • Patent number: 11498952
    Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: November 15, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
  • Patent number: 11497792
    Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 15, 2022
    Inventors: Ravindra Kumar, Asya Grinberg
  • Patent number: 11478510
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: October 25, 2022
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Patent number: 11471510
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • Patent number: 11466080
    Abstract: Provided herein are agents that hind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1. Further provided herein are agents that inhibit the function (e.g., the ability to repress Tsp-1) of Protease, Serine 2 (PRSS2) by inhibiting the binding of PRSS2 to LRP1. Methods of using these agents in treating cancer are also provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 11, 2022
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph S. Watnick
  • Patent number: 11466093
    Abstract: Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: October 11, 2022
    Assignee: The General Hospital Corporation
    Inventors: Glen S. Cho, Brian Seed
  • Patent number: 11464879
    Abstract: The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 11, 2022
    Inventors: Magdalena Krol, Irene Benni, Paola Baiocco, Tomasz Rygiel, Alberto Boffi
  • Patent number: 11466088
    Abstract: Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: October 11, 2022
    Assignee: Helix BioPharma Corp.
    Inventors: Heman Lap Man Chao, Wah Yau Wong, Baomin Tian, Marni Diane Uger